Foundayo vs Mounjaro: Pill Against Dual Agonist

Foundayo (orforglipron, Eli Lilly) vs Mounjaro (tirzepatide, Eli Lilly)

Last verified November 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The verdict

ATTAIN-1 put Foundayo at -11.1% over 72 weeks in obesity. SURPASS-2 put Mounjaro at -11.2 kg over 40 weeks in diabetes, and the identical molecule sold as Zepbound reached -20.9% in SURMOUNT-1. These are three trials in three populations, so read them as context, not as a ranking. Commercially, Foundayo costs $149–$349 a month through LillyDirect, while LillyDirect lists Mounjaro at $499 a month at every strength.

Side-by-side comparison

Foundayo vs Mounjaro, side by side
FieldFoundayoMounjaro
How you take itA pill, once a day, with or without foodAn injection under the skin, once a week
How it worksA small-molecule GLP-1 receptor agonist — not a peptide, which is why it survives the stomachHits two receptors, GIP and GLP-1, rather than one
The dose ladderSix daily steps: 0.8, 2.5, 5.5, 9, 14.5, then 17.2 mgSix weekly steps: 2.5, 5, 7.5, 10, 12.5, then 15 mg
Weight lost in the pivotal trial-11.1% over 72 weeks at 17.2 mg, in obesity (ATTAIN-1; Foundayo label)-11.2 kg over 40 weeks at 15 mg, in diabetes (SURPASS-2). The same molecule sold as Zepbound reached -20.9% in SURMOUNT-1
Blood-sugar reduction in diabetesAbout -1.5 points over 40 weeks at the top dose (ACHIEVE-1; -1.24 to -1.48 across doses)-2.30% over 40 weeks at 15 mg, measured directly against semaglutide (SURPASS-2)
What it is approved to treatLong-term weight management, from April 2026. A diabetes filing is still with the FDAType 2 diabetes only. For weight, the same molecule is sold as Zepbound
Whether a trial proved it prevents heart attacks and strokesNo trial has reported. One is plannedSURPASS-CVOT (2025): noninferior to dulaglutide (HR 0.92); MACE indication on the label
What it costs if you pay cash$149–$349/mo via LillyDirect, by dose$499/mo via LillyDirect self-pay at every strength

What each one costs in the compounded market

Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.

Foundayo — orforglipron

from $269 /mo

1 sellers publish a standing price. This is the lowest of all 1; the median is $269 a month.

Where to get orforglipron — a selection of sellers, not a price ranking

Mounjaro — tirzepatide

from $69 /mo

453 sellers publish a standing price. This is the lowest of all 453; the median is $228.28 a month.

Where to get tirzepatide — a selection of sellers, not a price ranking

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Are Foundayo and Mounjaro the same drug?

No. Foundayo is orforglipron and Mounjaro is tirzepatide — different molecules. Results with one do not predict results with the other.

Is Foundayo or Mounjaro cheaper?

On the manufacturers' own cash pricing: Foundayo at $149–$349/mo via LillyDirect, by dose, Mounjaro at $499/mo via LillyDirect self-pay at every strength. That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

What does a compounded version of each actually cost?

Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are orforglipron from $269 a month and tirzepatide from $69 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Foundayo to Mounjaro?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
  2. 2.Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). N Engl J Med. 2025. PMID: 40544435.
  3. 3.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.
  4. 4.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — FDA prescribing information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  5. 5.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — FDA prescribing information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  6. 6.Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes N Engl J Med. 2025. PMID: 41406444.
  7. 7.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022. PMID: 35658024.

See the full drug-vs-drug verdict index or provider rankings.